BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Type 1 Diabetes readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Type 1 Diabetes\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07224321-323@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Afrezza: Phase 2 readout est. (NCT07224321)
DESCRIPTION:Afrezza\, phase 2\, Type 1 Diabetes.\nStudy: INHALE-1st: Afrezz
 a® For Youth With Newly-Diagnosed Type 1 Diabetes\nEstimated primary comp
 letion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 frezza#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07224321
URL:https://assetmemo.bio/drug/afrezza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06334133-10930@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:cadisegliatin: Phase 3 readout est. (NCT06334133)
DESCRIPTION:cadisegliatin\, phase 3\, Type 1 Diabetes.\nStudy: Cadisegliati
 n as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes\nE
 stimated primary completion: April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cadisegliatin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06334133
URL:https://assetmemo.bio/drug/cadisegliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06147232-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT06147232)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Chronic Kidney Disease.\nStu
 dy: Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabet
 es With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding 
 Kidney hypOxia\nEstimated primary completion: May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06147232
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616206-10930@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:cadisegliatin: Phase 2 readout est. (NCT07616206)
DESCRIPTION:cadisegliatin\, phase 2\, Type 1 Diabetes.\nStudy: Cadisegliati
 n as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Wh
 o Are Using Hybrid Closed Loop (HCL) Systems\nEstimated primary completion
 : June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cadisegl
 iatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07616206
URL:https://assetmemo.bio/drug/cadisegliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435156-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT06435156)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Heart Failure.\nStudy: Sotag
 liflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes\nEsti
 mated primary completion: 31 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06435156
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04786262-3443@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zimislecel: Phase 3 readout est. (NCT04786262)
DESCRIPTION:Zimislecel\, phase 3\, Type 1 Diabetes.\nStudy: A Safety\, Tole
 rability\, and Efficacy Study of VX-880 and VX-017 in Participants With Ty
 pe 1 Diabetes\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zimislecel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04786262
URL:https://assetmemo.bio/drug/zimislecel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696366-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sotagliflozin (Inpefa): Phase 1/2 readout est. (NCT05696366)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 1/2\, Type 1 Diabetes.\nStudy: C
 ombination Adjunctive Therapy to Address Multiple Metabolic Imbalances in 
 Type 1 Diabetes\nEstimated primary completion: January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05696366
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217302-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06217302)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Heart Failure.\nStudy: Sotag
 liflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes a
 nd Diabetic Kidney Disease\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sotagliflozin-inpefa#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06217
 302
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325201-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07325201)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Chronic Kidney Disease.\nStu
 dy: Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Usin
 g Dual Continuous Ketone and Glucose Monitoring.\nEstimated primary comple
 tion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sotagliflozin-inpefa#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07325201
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082063-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06082063)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Heart Failure.\nStudy: Multi
 factorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
 \nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06082063
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Heart Failure.\nStudy: Preci
 sion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421518-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07421518)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Type 1 Diabetes.\nStudy: Ket
 one Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in Peo
 ple With T1D on Adjunctive SGLT-2 Inhibitors\nEstimated primary completion
 : April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotagli
 flozin-inpefa#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07421518
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07211802-314@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT07211802)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Type 1 Diabetes.\nStudy: CKM
  For Safe Use of SGLT2i in Type 1 Diabetes\nEstimated primary completion: 
 31 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotagli
 flozin-inpefa#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07211802
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
